Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Alnylam Pharmaceuticals, Inc. operates as an early-stage therapeutics company. The Company discovers and develops drug and medicines for the treatment of human disease. Alnylam Pharmaceuticals serves health care sectors in the United States and the United Kingdom.
Website: alnylam.com


  • Good financial results growth rate 78.7% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (79.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -5.0% (LTM)
  • Share price is 75.6% higher than minimum and 48.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (75.8x vs 30.0x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ALNY
Share price, USD:  (+0.8%)251.65
year average price 349.68  


year start price 446.40 2025-09-26

max close price 491.22 2025-10-20

min close price 205.48 2026-07-30

current price 251.65 2026-09-25
Common stocks: 120 848 523

Dividend Yield:  0.0%
FCF Yield LTM: -5.0%
EV / LTM EBITDA: 75.8x
EV / EBITDA annualized: 31.1x
EV / Sales: 4.9x
Margin (EBITDA LTM / Revenue): 6.5%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 30 163
Net Debt ($m): -1 452
EV (Enterprise Value): 28 711
EBITDA LTM (млн $): 379
EV / LTM EBITDA: 75.8x
Price to Book: 127.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-28fool.com

Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

2025-12-07fool.com

Is Alnylam Pharmaceuticals a Millionaire Maker?

2025-11-30seekingalpha.com

American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades

2025-11-20reuters.com

UK's drug-cost watchdog recommends Alnylam's heart disease drug

2025-11-19seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-18zacks.com

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

2025-11-08businesswire.com

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

2025-10-31zacks.com

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

2025-10-30seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript

2025-10-30zacks.com

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-10-27
acceptedDate 2025-10-03 16:15:23 2025-07-31 08:11:22 2025-02-13 08:31:57 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37 2022-02-10 08:22:31 2021-02-11 16:13:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 249M 774M 2 248M 501M 660M 494M 1 828M 751M 319M 319M 1 037M 264M 844M 493M
costOfRevenue 197M 143M 323M 86M 69M 66M 310M 84M 85M 55M 169M 41M 140M 78M
grossProfit 1 052M 631M 1 925M 415M 591M 428M 1 518M 666M 233M 264M 869M 223M 704M 415M
grossProfitRatio 0.842 0.815 0.829 0.896 0.867 0.888 0.732 0.828 0.844
researchAndDevelopmentExpenses 359M 324M 1 126M 271M 294M 261M 1 004M 253M 249M 231M 883M 245M 792M 655M
generalAndAdministrativeExpenses 322M 323M 976M 221M 248M 211M 796M 199M 215M 184M 771M 236M 621M 588M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 322M 323M 976M 221M 248M 211M 796M 199M 215M 184M 771M 236M 621M 588M
otherExpenses 3M 0 0 0 1M -6M 0 -58M -35M -12M 0 0 -2M 0
operatingExpenses 684M 647M 2 102M 492M 543M 472M 1 800M 452M 463M 414M 1 654M 481M 1 413M 1 243M
costAndExpenses 881M 790M 2 425M 578M 611M 538M 2 110M 537M 549M 469M 1 822M 522M 1 553M 1 321M
interestIncome 29M 27M 122M 32M 29M 30M 96M 25M 21M 19M 25M 8M 2M 12M
interestExpense 44M 40M 142M 34M 33M 35M 121M 31M 30M 29M 156M 41M 143M 84M
depreciationAndAmortization 14M 14M 57M 14M 15M 14M 54M -32M 23M 6M 44M 23M 48M 35M
ebitda 297M 19M -179M -60M 37M -30M -258M 182M -244M -143M -927M -235M -662M -736M
ebitdaratio 0.238 0.024 -0.12 0.096 -0.061 0.242 -0.766 -0.449 -0.888
operatingIncome 368M -16M -177M -77M 49M -43M -282M 214M -230M -150M -785M -258M -709M -828M
operatingIncomeRatio 0.295 -0.021 -0.154 0.074 -0.088 0.285 -0.721 -0.469 -0.976
totalOtherIncomeExpensesNet -129M -19M -200M -32M -60M -20M -151M -58M -35M -23M -342M -148M -143M -27M
incomeBeforeTax 239M -35M -377M -109M -11M -64M -434M 151M -274M -172M -1 127M -406M -852M -856M
incomeBeforeTaxRatio 0.191 -0.046 -0.217 -0.017 -0.129 0.201 -0.86 -0.54 -1.536
incomeTaxExpense -12M 31M -99M 3M 6M 2M 7M 3M 2M 2M 4M -23 000 680 000 3M
netIncome 251M -66M -278M -112M -17M -66M -440M 148M -276M -174M -1 131M -406M -853M -858M
netIncomeRatio 0.201 -0.086 -0.223 -0.026 -0.133 0.197 -0.866 -0.545 -1.536
eps 1.91 -0.51 -2.18 -0.87 -0.13 -0.52 -3.52 1.18 -2.21 -1.4 -9.3 -3.32 -7.2 -7.46
epsdiluted 1.84 -0.51 -0.87 -0.13 -0.52 1.15 -2.21 -1.4 -3.32
weightedAverageShsOut 131M 130M 128M 129M 127M 126M 125M 125M 125M 124M 122M 122M 118M 115M
weightedAverageShsOutDil 137M 130M 128M 129M 127M 126M 125M 131M 125M 124M 122M 122M 118M 115M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-10 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -20M -26M -131M -141M -73M
ebit -236M -312M -971M -709M -771M
nonOperatingIncomeExcludingInterest 59M 30M 186M 471 000 -57M
netIncomeFromContinuingOperations -278M -440M -1 131M -853M -858M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -278M -440M -1 131M -853M -858M
epsDiluted -2.18 -3.52 -9.3 -7.2 -7.46

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-10-27
acceptedDate 2025-10-03 16:15:23 2025-07-31 08:11:22 2025-02-13 08:31:57 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37 2022-02-10 08:22:31 2021-02-11 16:13:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 490M 1 114M 966M 1 100M 968M 682M 813M 1 033M 658M 672M 866M 1 073M 820M 497M
shortTermInvestments 1 234M 1 744M 1 728M 1 672M 1 656M 1 689M 1 627M 1 373M 1 400M 1 398M 1 326M 1 192M 1 616M 1 378M
cashAndShortTermInvestments 2 725M 2 858M 2 695M 2 772M 2 625M 2 371M 2 439M 2 406M 2 058M 2 071M 2 192M 2 265M 2 436M 1 874M
netReceivables 965M 567M 405M 354M 309M 321M 328M 325M 221M 219M 238M 185M 199M 602M
inventory 75M 72M 79M 76M 84M 94M 89M 96M 100M 132M 129M 115M 86M 75M
otherCurrentAssets 188M 147M 117M 154M 155M 202M 126M 158M 145M 119M 133M 126M 0 0
totalCurrentAssets 3 953M 3 644M 3 295M 3 355M 3 173M 2 989M 2 983M 2 985M 2 524M 2 541M 2 692M 2 691M 2 809M 2 615M
propertyPlantEquipmentNet 693M 692M 694M 703M 715M 719M 726M 729M 736M 738M 739M 734M 734M 707M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 54M 0 0 0 52M 52M 0 -10M -27M -26M 0 0 0 0
taxAssets 99M 104M 117M 0 0 0 10M 0 0 0 0 0 0 0
otherNonCurrentAssets 53M 126M 134M 146M 69M 65M 111M 135M 169M 139M 115M 111M 101M 86M
totalNonCurrentAssets 899M 922M 945M 850M 837M 836M 847M 854M 878M 851M 854M 844M 835M 792M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 4 852M 4 566M 4 240M 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M 3 643M 3 407M
accountPayables 118M 102M 88M 71M 74M 78M 56M 74M 60M 62M 98M 41M 73M 52M
shortTermDebt 160M 144M 113M 42M 104M 88M 0 42M 42M 43M 0 42M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 3M 15M 55M 71M 69M 77M 103M 77M 35M 36M 42M 144M 149M 127M
otherCurrentLiabilities 1 275M 1 040M 214M 1 037M 809M 699M 177M 757M 632M 532M 171M 546M 131M 111M
totalCurrentLiabilities 1 555M 1 301M 1 186M 1 221M 1 055M 942M 968M 950M 769M 673M 768M 773M 696M 585M
longTermDebt 2 613M 2 596M 2 359M 1 260M 2 605M 2 359M 1 021M 1 268M 1 272M 1 277M 1 017M 1 282M 676M 191M
deferredRevenueNonCurrent 0 0 0 1M 2M 186M 188M 196M 213M 191M 194M 133M 152M 225M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 239M 238M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 449M 418M 398M 1 691M 350M 320M 1 631M 1 592M 1 556M 1 509M 1 465M 2 604M 1 250M 1 096M
totalNonCurrentLiabilities 3 062M 3 015M 2 987M 2 952M 2 957M 3 102M 3 083M 3 055M 3 041M 2 978M 2 937M 2 830M 2 359M 1 806M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 223M 271M 271M 278M 281M 238M 285M 289M 295M 302M 303M 308M 322M 330M
totalLiabilities 4 618M 4 315M 4 173M 4 173M 4 013M 4 044M 4 051M 4 005M 3 811M 3 651M 3 705M 3 603M 3 055M 2 391M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
retainedEarnings -7 160M -7 412M -7 288M -7 204M -7 092M -7 076M -7 010M -6 872M -7 019M -6 743M -6 569M -6 362M -5 438M -4 585M
accumulatedOtherComprehensiveIncomeLoss -22M -30M -35M -25M -35M -27M -23M -32M -37M -39M -45M -44M -33M -44M
othertotalStockholdersEquity 7 415M 7 691M 7 260M 7 123M 6 882M 6 737M 6 647M 6 522M 6 337M
totalStockholdersEquity 234M 251M 67M 32M -3M -219M -221M -166M -408M -259M -158M -68M 588M 1 016M
totalEquity 234M 251M 67M 32M -3M -219M -221M -166M -408M -259M -158M -68M 588M 1 016M
totalLiabilitiesAndStockholdersEquity 4 852M 4 566M 4 205M 4 010M 3 824M 3 839M 3 402M 3 392M 3 535M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 852M 4 566M 4 240M 4 205M 4 010M 3 824M 3 830M 3 839M 3 402M 3 392M 3 546M 3 535M 3 643M 3 407M
totalInvestments 1 288M 1 744M 1 728M 1 672M 1 708M 1 742M 1 627M 1 363M 1 372M 1 373M 1 326M 1 192M 1 616M 1 378M
totalDebt 2 773M 2 740M 2 743M 1 302M 2 708M 2 684M 1 305M 1 309M 1 314M 1 320M 1 320M 1 324M 998M 521M
netDebt 1 283M 1 626M 1 777M 202M 1 740M 2 002M 493M 276M 657M 648M 454M 251M 178M 25M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-10 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 405M 328M 238M 199M 102M
otherReceivables 0 0 0 0 500M
prepaids 0 0 0 88M 63M
totalPayables 88M 56M 98M 73M 52M
otherPayables 0 0 0 0 0
accruedExpenses 673M 591M 415M 302M 258M
capitalLeaseObligationsCurrent 42M 42M 42M 41M 37M
capitalLeaseObligationsNonCurrent 230M 243M 261M 281M 293M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 7 388M 6 811M 6 455M 6 058M 5 644M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY ALNY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-10-27
acceptedDate 2025-10-03 16:15:23 2025-07-31 08:11:22 2025-02-13 08:31:57 2024-10-31 08:22:09 2024-08-01 08:22:58 2024-05-02 08:21:02 2024-02-15 16:23:12 2023-11-02 08:22:13 2023-08-03 08:18:45 2023-05-04 08:22:22 2023-02-23 08:19:23 2022-10-27 08:15:37 2022-02-10 08:22:31 2021-02-11 16:13:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 251M -66M -278M -112M -17M -66M -440M 148M -276M -174M -1 131M -406M -853M -858M
depreciationAndAmortization 14M 14M 57M 49M 15M 14M 97M 24M 23M 26M 86M 21M 90M 74M
deferredIncomeTax 6M 10M -107M 0 0 0 0 39M 29M 0 0 0 -56M -54M
stockBasedCompensation 108M 112M 272M 46M 89M 45M 222M 64M 76M 40M 231M 128M 166M 140M
changeInWorkingCapital -205M 50M -214M 31M -49M -121M 11M 26M 65M -86M -36M 5M -163M -13M
accountsReceivables -400M -137M -87M -37M 10M 410 000 -88M -108M -3M 19M -46M -38M -102M -56M
inventory 5M 11M 14M 6M 7M 22 000 18M 5M 2M -403 000 -34M -8M -26M -35M
accountsPayables 224M 182M 91M 84M 74M -5M 81M 119M 83M -82M 192M 70M 88M 117M
otherWorkingCapital -33M -6M -232M -22M -140M -117M -509 000 10M -17M -23M -148M -19M -123M -38M
otherNonCashItems 151M 35M 262M 30M 114M 124M 215M 59M 24M 28M 309M 137M 174M 96M
netCashProvidedByOperatingActivities 325M 154M -8M 44M 124M -82M 104M 359M -59M -166M -541M -115M -642M -615M
investmentsInPropertyPlantAndEquipment -12M -14M -34M -4M -8M -13M -62M -17M -16M -14M -72M -17M -76M -70M
acquisitionsNet 0 0 0 0 0 0 0 -11M 0 -49M 0 0 0 0
purchasesOfInvestments -210M -469M -1 712M -450M -316M -460M -1 824M -421M -377M -436M -1 977M -157M -1 656M -2 026M
salesMaturitiesOfInvestments 723M 332M 1 572M 424M 358M 405M 1 554M 432M 384M 373M 2 232M 493M 1 464M 1 692M
otherInvestingActivites -450 000 9M 0 42M 40M 6M 0 49M -5M
netCashUsedForInvestingActivites 501M -141M -30M 34M -68M -11M -9M -76M 314M
debtRepayment -494M 0 0 0 0 0 0 0 0
commonStockIssued -131M 81M 108M 133M 26M 25M 0 27M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 176M -27M -5M 131M 3M 8M 53M 19M 297M
netCashUsedProvidedByFinancingActivities -448M 54M 103M 131M 29M 33M 53M 46M 297M
effectOfForexChangesOnCash -927 000 28M -15M 15M -3M -10M 6M -7M -130 000 2M -7M 2M -9M 5M
netChangeInCash 377M 94M 154M 134M 287M -131M -54M 375M -14M -194M 46M 498M 323M -51M
cashAtEndOfPeriod 1 493M 1 116M 969M 1 102M 968M 682M 815M 1 035M 660M 674M 869M 1 075M 822M 499M
cashAtBeginningOfPeriod 1 116M 1 022M 815M 968M 682M 813M 869M 660M 674M 869M 822M 578M 499M 550M
operatingCashFlow 325M 154M -8M 44M 124M -82M 104M 359M -59M -166M -541M -115M -642M -615M
capitalExpenditure -12M -14M -34M -4M -8M -13M -62M -17M -16M -14M -72M -17M -76M -70M
freeCashFlow 313M 139M -43M 40M 116M -94M 42M 342M -75M -180M -613M -132M -718M -685M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-23 2022-02-10 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 58M -4M -13M -4M -31M
netCashProvidedByInvestingActivities -117M -336M 169M -273M -436M
netDebtIssuance 0 0 254M 500M 200M
longTermNetDebtIssuance 0 0 254M 500M 200M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 303M 147M 259M 246M 99M
netCommonStockIssuance 303M 147M 259M 246M 99M
commonStockIssuance 303M 147M 259M 246M 99M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -9M 25M -88M 501M 695M
netCashProvidedByFinancingActivities 294M 172M 426M 1 247M 995M
incomeTaxesPaid 14M 0 0 0 0
interestPaid 68M 0 0 0 0

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-09-02 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2026-08-30 ET
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
2026-08-24 ET
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
2026-07-30 ET
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
2026-07-16 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
2026-07-15 ET
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
2026-06-25 ET
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
2026-06-12 ET
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
2026-06-10 ET
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
2026-06-03 ET
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
2026-05-19 12:30 ET
Alnylam Issues 2025 Corporate Responsibility Report
2026-05-12 ET
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
2026-05-07 ET
Alnylam to Webcast Presentations at Upcoming Investor Conferences
2026-05-04 ET
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
2026-04-30 ET
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
2026-04-16 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
2026-03-30 ET
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
2026-03-24 ET
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
2026-03-23 ET
Nationwide Effort Targets Diagnosis Delays, Care Gaps for a Life Threatening Heart Disease
2026-03-10 ET
Alnylam to Webcast TTR Investor Webinar
2026-02-23 ET
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
2026-02-12 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
2026-01-29 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
2026-01-11 ET
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
2026-01-05 ET
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
2025-12-17 ET
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
2025-12-11 ET
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
2025-12-03 ET
Alnylam Pharmaceuticals Announces Changes to Board of Directors
2025-11-08 ET
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
2025-11-04 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2025-10-30 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
2025-10-16 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
2025-10-01 ET
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
2025-09-28 ET
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
2025-09-09 ET
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
2025-09-08 ET
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
2025-08-31 ET
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
2025-08-30 ET
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
2025-08-30 ET
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
2025-08-27 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2025-08-11 ET
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
2025-08-05 ET
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
2025-07-31 ET
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
2025-07-17 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
2025-06-18 ET
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
2025-06-09 ET
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
2025-05-28 ET
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-20 ET
Alnylam Issues 2024 Corporate Responsibility Report
2025-05-17 ET
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
2025-05-12 ET
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
2025-05-05 ET
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
2025-05-01 ET
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
2025-04-28 ET
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
2025-04-17 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
2025-04-01 ET
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
2025-03-29 ET
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
2025-03-28 ET
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
2025-03-20 ET
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
2025-03-11 ET
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
2025-03-05 ET
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
2025-02-25 ET
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
2025-02-13 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
2025-01-30 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
2025-01-12 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
2025-01-06 ET
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference
2024-11-27 ET
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
2024-11-25 ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
2024-11-04 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2024-10-31 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-10-30 12:00 ET
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
2024-10-17 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
2024-10-16 12:00 ET
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
2024-10-09 11:00 ET
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
2024-09-29 13:00 ET
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
2024-09-26 12:00 ET
Alnylam to Webcast TTR Investor Day
2024-08-30 10:00 ET
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
2024-08-28 20:00 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2024-08-07 12:00 ET
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
2024-08-01 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-07-18 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
2024-06-24 11:00 ET
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
2024-05-07 12:00 ET
Alnylam Issues 2023 Corporate Responsibility Report
2024-05-02 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-04-30 11:00 ET
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
2024-04-18 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024-04-07 12:00 ET
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
2024-03-20 12:00 ET
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
2024-03-13 11:30 ET
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
2024-03-05 12:30 ET
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
2024-02-27 13:30 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2024-02-15 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
2024-01-29 13:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
2024-01-09 13:05 ET
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
2024-01-07 23:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
2024-01-02 12:30 ET
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 12:30 ET
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
2023-12-06 13:00 ET
Alnylam to Webcast Virtual R&D Day
2023-11-30 13:00 ET
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
2023-11-11 21:00 ET
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
2023-11-07 13:00 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2023-11-02 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-10-26 18:00 ET
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
2023-10-25 21:19 ET
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
2023-10-25 15:05 ET
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-10-19 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
2023-10-09 11:30 ET
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-10-06 11:00 ET
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
2023-09-13 20:57 ET
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-09-13 11:00 ET
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-09-07 11:00 ET
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
2023-09-06 07:00 ET
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals
2023-08-03 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-08-02 12:30 ET
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
2023-07-24 05:00 ET
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
2023-07-20 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
2023-07-19 21:00 ET
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
2023-07-17 06:21 ET
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-06-30 13:00 ET
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-06-05 20:00 ET
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-20 14:50 ET
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
2023-05-04 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-05-03 20:00 ET
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
2023-05-03 12:00 ET
Alnylam Issues 2022 Corporate Responsibility Report
2023-04-26 20:05 ET
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-04-26 20:05 ET
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2023-04-20 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
2023-03-09 12:00 ET
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
2023-03-08 12:00 ET
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
2023-03-01 13:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2023-02-23 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
2023-02-21 13:00 ET
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-02-02 13:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
2023-01-08 23:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
2023-01-05 21:00 ET
Alnylam Announces Updates to its Board of Directors
2023-01-03 21:00 ET
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 13:00 ET
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
2022-12-15 13:00 ET
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
2022-12-08 21:00 ET
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2022-12-08 12:00 ET
Alnylam to Webcast Virtual R&D Day
2022-12-01 12:00 ET
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
2022-11-09 13:00 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2022-10-27 18:00 ET
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
2022-10-27 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
2022-10-13 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
2022-10-07 00:30 ET
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
2022-09-30 18:00 ET
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
2022-09-21 20:00 ET
Alnylam Announces New Management Appointments
2022-09-20 11:00 ET
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
2022-09-19 12:00 ET
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
2022-09-15 11:00 ET
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
2022-09-15 11:00 ET
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
2022-09-13 12:00 ET
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
2022-09-13 10:00 ET
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
2022-09-12 10:45 ET
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
2022-09-08 06:30 ET
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
2022-09-06 12:00 ET
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-29 12:00 ET
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
2022-08-24 20:00 ET
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
2022-08-18 11:30 ET
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
2022-08-03 11:00 ET
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
2022-08-02 12:00 ET
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
2022-07-28 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
2022-07-27 12:00 ET
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
2022-07-22 12:17 ET
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
2022-07-18 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
2022-06-13 23:22 ET
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
2022-06-09 11:00 ET
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
2022-06-02 20:00 ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2022-06-02 15:42 ET
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
2022-05-24 11:00 ET
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2022-05-23 11:00 ET
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
2022-05-04 12:00 ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2022-04-28 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
2022-04-14 12:30 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
2022-04-05 20:00 ET
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
2022-04-04 11:30 ET
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
2022-03-22 12:00 ET
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
2022-03-17 11:30 ET
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
2022-03-16 11:30 ET
Alnylam Issues 2021 Corporate Responsibility Report
2022-03-01 12:00 ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
2022-02-28 21:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2022-02-28 12:00 ET
Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
2022-02-10 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
2022-02-08 13:30 ET
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
2022-01-24 13:38 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
2022-01-21 12:30 ET
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
2022-01-18 14:05 ET
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
2022-01-14 12:00 ET
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
2022-01-11 14:00 ET
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
2022-01-09 18:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
2022-01-06 12:30 ET
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
2022-01-04 12:30 ET
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
2022-01-03 12:00 ET
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
2021-12-22 21:23 ET
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
2021-12-22 12:00 ET
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
2021-12-21 21:30 ET
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
2021-12-20 21:00 ET
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
2021-12-20 12:00 ET
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
2021-12-14 12:00 ET
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
2021-12-02 13:00 ET
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
2021-11-23 13:00 ET
Alnylam to Webcast Presentations at Upcoming Investor Conferences
2021-11-19 12:00 ET
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
2021-11-13 13:00 ET
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
2021-11-12 13:00 ET
Alnylam to Webcast Virtual R&D Day
2021-11-08 12:00 ET
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
2021-11-05 17:30 ET
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2021-11-01 20:00 ET
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
2021-10-28 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
2021-10-28 11:55 ET
Alnylam Announces Planned CEO Leadership Transition
2021-10-27 20:00 ET
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
2021-10-14 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
2021-10-13 11:30 ET
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
2021-09-29 11:30 ET
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
2021-09-28 20:00 ET
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
2021-09-13 11:00 ET
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2021-09-07 11:00 ET
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
2021-09-01 20:00 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2021-08-09 11:00 ET
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
2021-08-03 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
2021-07-29 21:00 ET
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
2021-07-29 11:00 ET
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
2021-07-21 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
2021-06-30 11:00 ET
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
2021-06-24 11:00 ET
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
2021-06-23 11:00 ET
Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
2021-06-07 11:30 ET
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
2021-06-01 11:00 ET
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
2021-05-26 20:00 ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2021-05-11 11:00 ET
Alnylam Announces New Advances in ATTR Amyloidosis Program
2021-05-04 12:00 ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2021-05-03 11:00 ET
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
2021-04-29 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
2021-04-19 18:00 ET
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
2021-04-15 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
2021-04-11 14:28 ET
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
2021-04-06 12:00 ET
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
2021-03-31 21:00 ET
Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
2021-03-29 12:00 ET
Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
2021-03-23 12:00 ET
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
2021-03-11 13:30 ET
Alnylam Issues Inaugural Corporate Responsibility Summary
2021-03-09 13:00 ET
Soleo Health to Administer Alnylam Pharmaceuticals’ GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults
2021-02-22 21:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2021-02-18 21:00 ET
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
2021-02-11 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
2021-01-28 13:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
2021-01-10 18:00 ET
Alnylam Launches “Alnylam P⁵x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
2021-01-07 12:00 ET
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
2021-01-04 21:00 ET
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
2020-12-21 13:00 ET
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
2020-12-15 12:00 ET
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
2020-12-08 13:00 ET
Alnylam to Webcast Virtual R&D Day
2020-12-07 12:30 ET
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
2020-12-03 18:52 ET
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
2020-12-03 13:07 ET
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)
2020-12-03 13:00 ET
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
2020-11-25 13:00 ET
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
2020-11-24 12:01 ET
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers
2020-11-24 12:00 ET
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
2020-11-19 12:00 ET
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
2020-11-13 14:00 ET
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
2020-11-05 13:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
2020-11-02 21:00 ET
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2020-10-30 11:00 ET
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
2020-10-29 19:06 ET
Alnylam Named a Top Biopharma Employer by Science Magazine
2020-10-22 20:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
2020-10-22 14:00 ET
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
2020-10-16 10:00 ET
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
2020-09-30 11:00 ET
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
2020-09-28 20:00 ET
Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference
2020-09-03 11:30 ET
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable
2020-09-02 12:00 ET
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2020-08-06 12:00 ET
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity
2020-08-06 11:30 ET
Alnylam Announces Planned Transition of Barry Greene, President
2020-08-03 11:30 ET
Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)
2020-07-23 12:00 ET
Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results
2020-07-13 11:28 ET
Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran
2020-07-08 11:57 ET
Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States
2020-06-30 13:00 ET
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
2020-06-18 11:00 ET
Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series
2020-06-17 20:00 ET
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
2020-06-10 21:07 ET
Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine
2020-06-07 11:15 ET
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
2020-06-02 12:00 ET
Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program
2020-06-01 11:00 ET
Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
2020-05-26 20:00 ET
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2020-05-26 11:00 ET
Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1
2020-05-22 16:30 ET
Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020
2020-05-11 12:00 ET
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2020-05-06 12:00 ET
Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity
2020-05-04 11:30 ET
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
2020-04-23 12:00 ET
Alnylam to Webcast Conference Call Discussing First Quarter 2020 Financial Results
2020-04-14 11:00 ET
Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis
2020-04-13 20:00 ET
Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference
2020-04-13 11:30 ET
Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics
2020-04-07 11:00 ET
Alnylam Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration and Submits Marketing Authorization Application to the European Medicines Agency for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
2020-04-06 11:00 ET
Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs
2020-04-02 11:00 ET
Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19
2020-03-25 10:00 ET
Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran), the First-in-Class ‘Gene-Silencing’ RNAi Therapeutic
2020-03-04 12:00 ET
 Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
2020-03-03 12:00 ET
Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents
2020-02-27 21:00 ET
Alnylam Announces Changes to its Board of Directors
2020-02-26 13:00 ET
Alnylam Announces Approval in Brazil of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2020-02-25 12:00 ET
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2020-02-20 13:00 ET
Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference
2020-02-18 12:00 ET
Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy
2020-02-06 13:00 ET
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity
2020-01-31 11:00 ET
Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents
2020-01-27 21:00 ET
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results
2020-01-12 23:00 ET
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates
2020-01-10 21:00 ET
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
2020-01-06 12:00 ET
Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference
2019-12-17 12:00 ET
Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
2019-11-26 13:00 ET
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
2019-11-22 12:00 ET
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
2019-11-20 19:21 ET
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
2019-11-20 19:03 ET
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
2019-11-19 13:00 ET
Alnylam Announces Second Annual Advocacy for Impact Grants Program
2019-11-12 21:00 ET
Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference
2019-11-09 17:00 ET
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
2019-10-31 12:00 ET
Alnylam Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Period Activity
2019-10-24 18:11 ET
Alnylam Named #1 Biopharma Employer by Science Magazine
2019-10-23 12:00 ET
Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results
2019-10-15 10:00 ET
Alnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
2019-10-10 11:30 ET
Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
2019-09-26 12:30 ET
Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference
2019-09-16 11:30 ET
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
2019-09-11 12:30 ET
1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
2019-09-10 09:30 ET
Alnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
2019-04-15 11:00 ET
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
2019-04-12 22:01 ET
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
2019-04-08 11:00 ET
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
2019-04-08 11:00 ET
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

SEC forms

Show financial reports only

SEC form 10
2026-07-30 12:11 ET
Alnylam Pharmaceuticals reported for 2026 q2
SEC form 8
2026-07-30 12:06 ET
Alnylam Pharmaceuticals reported for 2026 q2
SEC form 8
2026-07-30 12:06 ET
Alnylam Pharmaceuticals published news for 2026 q2
SEC form 10
2026-04-30 12:16 ET
Alnylam Pharmaceuticals published news for 2026 q1
SEC form 8
2026-04-30 12:04 ET
Alnylam Pharmaceuticals reported for 2026 q1
SEC form 8
2026-04-30 12:04 ET
Alnylam Pharmaceuticals published news for 2026 q1
SEC form 10
2026-02-12 08:12 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-12 08:05 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-12 08:05 ET
Alnylam Pharmaceuticals reported for 2025 q4
SEC form 8
2026-01-12 12:30 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-12 12:30 ET
Alnylam Pharmaceuticals published news for 2025 q4
SEC form 8
2025-12-11 07:25 ET
Alnylam Pharmaceuticals published news for 2025 q3
SEC form 8
2025-12-11 07:25 ET
Alnylam Pharmaceuticals published news for 2025 q3
SEC form 10
2025-10-30 12:16 ET
Alnylam Pharmaceuticals reported for 2025 q3
SEC form 8
2025-10-30 12:06 ET
Alnylam Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-30 12:06 ET
Alnylam Pharmaceuticals reported for 2025 q3
SEC form 8
2025-09-10 11:30 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-10 11:30 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-10 11:30 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 10
2025-07-31 12:11 ET
Alnylam Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-31 12:05 ET
Alnylam Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-31 12:05 ET
Alnylam Pharmaceuticals reported for 2025 q2
SEC form 10
2025-05-01 12:15 ET
Alnylam Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Alnylam Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-13 13:31 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q4
SEC form 10
2024-10-31 08:22 ET
Alnylam Pharmaceuticals reported for 2024 q3
SEC form 10
2024-10-31 00:00 ET
Alnylam Pharmaceuticals reported for 2024 q3
SEC form 10
2024-08-01 08:22 ET
Alnylam Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Alnylam Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-02 08:21 ET
Alnylam Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Alnylam Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Alnylam Pharmaceuticals reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 08:22 ET
Alnylam Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 08:10 ET
Alnylam Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-03 08:18 ET
Alnylam Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-03 08:10 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-26 17:15 ET
Alnylam Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-30 09:03 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Alnylam Pharmaceuticals published news for 2023 q1
SEC form 10
2023-02-23 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Alnylam Pharmaceuticals published news for 2022 q4
SEC form 10
2022-10-27 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q3
SEC form 8
2022-07-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q2
SEC form 10
2022-07-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q2
SEC form 8
2022-04-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q1
SEC form 10
2022-04-28 00:00 ET
Alnylam Pharmaceuticals reported for 2022 q1
SEC form 8
2022-02-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q4
SEC form 8
2021-10-28 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q3
SEC form 8
2021-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q2
SEC form 8
2021-04-29 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Alnylam Pharmaceuticals published news for 2021 q1